Terms: = Lymphoma AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Staging
8 results:
1. Myeloid/Lymphoid Neoplasm with fgfr1 Rearrangement Presenting with Polycythemia Vera and T-cell Acute Lymphoblastic Leukemia.
Marinelli LM; Romain JT; Ehman W; Ortega V; Velagaleti G; Gibbons TF; Nazario-Toole A; Holmes AR
Cancer Genet; 2023 Aug; 276-277():43-47. PubMed ID: 37480761
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic and predictive biomarkers in lung cancer. A review.
Thunnissen E; van der Oord K; den Bakker M
Virchows Arch; 2014 Mar; 464(3):347-58. PubMed ID: 24420742
[TBL] [Abstract] [Full Text] [Related]
3. A rare pediatric case of a thymic cytotoxic and lymphoblastic T/NK cell lymphoma.
Gaiser T; Haedicke W; Becker MR
Int J Clin Exp Pathol; 2010 Mar; 3(4):437-42. PubMed ID: 20490334
[TBL] [Abstract] [Full Text] [Related]
4. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
Scarisbrick JJ; Whittaker S; Evans AV; Fraser-Andrews EA; Child FJ; Dean A; Russell-Jones R
Blood; 2001 Feb; 97(3):624-30. PubMed ID: 11157477
[TBL] [Abstract] [Full Text] [Related]
6. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC lymphoma Group controlled clinical trials: 1964-1987.
Tubiana M; Henry-Amar M; Carde P; Burgers JM; Hayat M; Van der Schueren E; Noordijk EM; Tanguy A; Meerwaldt JH; Thomas J
Blood; 1989 Jan; 73(1):47-56. PubMed ID: 2462943
[TBL] [Abstract] [Full Text] [Related]
7. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.
Carde P; Burgers JM; Henry-Amar M; Hayat M; Sizoo W; Van der Schueren E; Monconduit M; Noordijk EM; Lustman-Marechal J; Tanguy A
J Clin Oncol; 1988 Feb; 6(2):239-52. PubMed ID: 2578012
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research and Treatment of Cancer.
Carde P; Hayat M; Cosset JM; Somers R; Burgers JM; Sizoo W; Meerwaldt JH; Hagenbeek A; Monconduit M; van der Schueren E
NCI Monogr; 1988; (6):303-10. PubMed ID: 3352775
[TBL] [Abstract] [Full Text] [Related]
